ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May 9, 2017, Aralez Pharmaceuticals Inc., a company formed
under the laws of the Province of British Columbia, Canada (the
Company), issued a press release announcing its results of
operations for the quarter ended March 31, 2017. The full text of
such press release is furnished as Exhibit99.1 to this report and
is incorporated herein by reference.
Item 7.01. Regulation FD Disclosures.
As previously announced, the Company will conduct a conference
call today, Tuesday, May 9, 2017 at 9:00 a.m.ET, to discuss its
2017first quarter financial results and recent highlights. The
presentation slides to be used during the call will be available
on the Investors section of the Companys website
(http://www.aralez.com) under the Presentations Webcasts tab
beginning at 9:00 a.m.ET on Tuesday, May 9, 2017. A question and
answer session will follow the presentation. The conference call
and the presentation slides will be simultaneously webcast on the
Investors section of the Companys website under the Presentations
Webcasts tab beginning at 9:00 a.m.ET on Tuesday, May 9, 2017,
and will remain available for future review for two weeks after
the event. The information contained in, or that can be accessed
through the Companys website, is not a part of this filing.
Item9.01. Financial Statements and Exhibits
(d)List of Exhibits
|
EXHIBIT NO. |
DESCRIPTION |
|
99.1 |
Press Release, dated May 9, 2017, issued by Aralez |
– 2-
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID). ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Recent Trading Information
ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) closed its last trading session down -0.24 at 1.21 with 3,202,923 shares trading hands.
